Cancer Research

Article	Citations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up	477
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19	191
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer	189
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer	181
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated	158
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l	154
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response	146
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC	140
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer	133
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR	127
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression	125
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj	119
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer	118
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience	117
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer	114
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality	113
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy	112
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS	112
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study	105
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer	105
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with	105
Abstract ES8-2: Can radiation replace ALND after positive SLNB?	100
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer	97
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast	95
Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer	94

Abstract P5-13-17: PD-L1 expression in breast to brain metastases	91
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer	88
Abstract PO-119: DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment	86
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity	86
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity	81
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts	80
Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma	78
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors	77
Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype	76
Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL	75
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy	75
Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression	73
Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study	73
Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer	73
Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity	72
MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages	72
Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage	71
SMARCA4 Inhibits Breast Cancer Progression and Metastasis through RHOA Suppression	71
Fam20C Regulates Bone Resorption and Breast Cancer Bone Metastasis through Osteopontin and BMP4	71
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants	70
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk	70
Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia	69
Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma	68
Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma	68
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance	67
Abstract 2074: MALDI-ICC: a new tool for high-plex, multiomic profiling of single cells for cancer research and cancer therapy	66
Abstract 1913: Cystic fluid acetylated polyamines predict risk of malignancy of intraductal papillary mucinous neoplasms of the pancreas	65
Abstract 3731: The role of dietary patterns and microbiome composition in colorectal cancer survival: The ColoCare Study	65
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery	65
Abstract 3727: Physical activity patters according to demographic, social, and clinical correlates among breast cancer survivors	65
Abstract 1320: Nanotopographical cues enhance glioblastoma migration: Harnessing biomimetic matrices and machine learning to uncover cancer invasion	64
Abstract 3688: Correlation between natural killer cell sensitivity and epithelial mesenchymal transition morphology: A cell morphology based screening for NK cell susceptible tumor cells	64
Abstract 294: TFEB nuclear persistence predicts sensitivity to lysosomal inhibition in therapy-induced senescent thyroid cancer cells	63
Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays	63
Abstract 3655: Leveraging alternative AIML technologies to identify predictive biomarkers for chemotherapy selection: An analysis of the COMPASS trial evaluating chemotherapy response in advanced PDAC	62
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA)	62
Abstract 47: Optimizing in vivo establishment of hormone receptor-positive breast cancer patient-derived xenografts for therapeutic assessment	61
Abstract 2873: Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC	61
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer	61
Abstract 1510: Glutathione-oxidation of ovarian tumor deubiquitinase-1 promotes lung adenocarcinoma survival through stabilizing system xc-	61
Abstract 1120: Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study	60
Abstract 679: Orthogonal confirmation using the Pacbio®two step universal adapter amplicon protocol to validate a comprehensive genomic profiling assay for hematologic malignancies	60
Abstract 7210: Predicting drug response heterogeneity in AML: novel AI-enabled proteomics model for a prospective clinical trial	59
Abstract 7085: Analysis of gene expression pattern of glycosphingolipid synthases using tumor tissues from breast cancer patients to identify key targets for early diagnosis and protection of recurren	59
Abstract 7502: Radiation-induced transcriptomic reprogramming of mesenchymal glioblastoma stem cells reveals key pathways and potential targets	59
Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor	58
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer	57
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment	57
Abstract 1585: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model	57
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer	57

Abstract 365: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma	56
Abstract 611: Actinobacteria from macroalgae as a source of new anti-lymphoma compounds	56
Abstract 691: Decentralized pan-cancer tumor profiling: a comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDMTM	56
Abstract 768: Decode the antibody-drug conjugate surfaceome in metastatic urothelial cancer (DECODE-ADC)	56
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors	56
Abstract 1108: Tissue and circulating DNA methylation profiling can recapitulate SCLC heterogeneity to enable identification of new biomarkers of clinical relevance	55
Abstract 1072: MOSAIC Window: Spatial intra-tumoral heterogeneity characterization through large-scale spatial and single-nuclei multi-omics profiling	55
Abstract 1066: OncoKBTM, MSK’s precision oncology knowledge base: 2024 updates	55
Abstract 244: Identification of proteins in the oncogenic FLT3-ITD signaling pathway using the APEX2 system	55
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation	54
Abstract 1520: Obesity delays melanoma resistance to BRAF/MEKi inhibitors and alters melanoma metabolism	54
Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease	54
Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing	53
Abstract 7205: Targeting diverse pathways for the treatment of KRAS driven non-small cell lung cancer	52
Abstract 2651: Nuclear prothymosin α suppresses TGF-β-induced EMT by stabilizing smad7: implications for lung cancer progression and metastasis	52
Abstract 4822: Efficacy of 4-1BB-costimulated NKG2D CAR-T cells for synovial sarcoma in comparison with CAR-T cells targeting other antigens	52
Abstract 5726: QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors	52
Abstract 5166: Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune mic	52
Abstract 6681: Identification of a panel of four exosomal microRNAs driving T cell dysfunction in the tumor-immune microenvironment of high-grade serous ovarian cancer	51
Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model	51
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases	51
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin	51
Abstract 88: Ephrin receptor A4 is a regulator of metastatic colonization in triple negative breast cancer	50
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:01	50
Abstract 2119: Targeting KIT in chromophobe renal cell carcinoma	50
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma	50
Abstract 140: Profiling ECM biomarkers PRO-C3 and PRO-C5 in plasma from patients with esophagogastric cancer	50
Abstract 6198: Framework for Pacific Island Cancer and Obesity Across the Lifespan: PICOLI, A multi-dataset analysis approach	49
Abstract 1348: Investigation of sex disparity in hepatocarcinogenesis using a hydrodynamic tail vein injection mouse model	49
Abstract 2804: Long non-coding RNA LINC01614 regulates ferroptosis-mediated carcinogenic phenotypes in papillary thyroid cancer	48
Abstract 2056: Development of a response prediction Model for venetoclax-based therapy utilizing molecular interactions among BCL2 family members	48
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma	48
Abstract 5105: Tumor treating fields (TTFields) alter nanomechanical attributes of cell-ECM complex in pancreatic ductal adenocarcinoma	47
Abstract 4173: Compensatory interactions between tryptophan catabolism and serine metabolism highlight potential vulnerabilities in TNBC cells with dysregulated de novo serine synthesis	47
Abstract 3915: An orthotopic model for murine urothelial carcinoma with response to standard of care checkpoint inhibitor treatment	47
Abstract 1719: Constitutive aryl hydrocarbon activity promotes resistance to bortezomib which is exacerbated by leptin and potentially involves Src phosphorylation by JAK2 in prostate cancer cells	47
Abstract 904: Mapping the T cell-cold phenotype to the colorectal cancer genome identifies POFUT1 as a driver of tumor T cell inhibition	47
Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells	46
Abstract 988: Impact of the COVID-19 pandemic on HPV vaccine hesitancy	46
Abstract 72: A case of immune therapy-refractory composite lymphoma: The complex interplay between two distinct tumors within a single spatial microenvironment	46
Abstract 3045: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death	46
Abstract 713: Utility of next generation sequencing multigene assay for comprehensive molecular profiling and targeted therapy in solid organ malignancies - An Indian experience	46
Abstract 1086: Introducing the Florida Cancer Research (FL CARES) Network and the Platform for Accelerating Collaborative Computational Cancer Research (PAC3R)	45
Abstract 7388: Trends of diagnosis disclosure among individuals with plasma cell disorders	45
Abstract 2485: A Bayesian framework for unraveling disease biology from spatially resolved single-cell omics datasets by combining unbiased approaches with biological priors for cell-based microdomain	45
Abstract 7446: Stratification of cell therapies in solid tumor organoids using deep learning-derived imaging metrics	45
Abstract 1470: Inhibition of protein myristoylation sensitizes pancreatic cancer cells to DNA damage agents	45
Abstract 2486: Decoding tumor evolution through fitness landscapes of aneuploid cells	45
Abstract 7035: Targeting Ewing sarcoma with a novel RBM39 degrader: DNA damage repair pathway effects	44
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices	44
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research	44
Abstract 4217: Effect of HDAC3 targeting on endometrial cancer progression and therapeutic potential	44
Abstract 5365: Comparison of whole genome sequencing and target capture sequencing in lung cancer	44
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein	44
Abstract 3793: Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats	44
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application	44
Abstract 7374: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review	44
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer	44
Abstract 3005: Discovery of a potential therapeutic mechanism for selected tumors via targeting PI3K and DDR pathways simultaneously with a novel orally available small molecule	44
Abstract 1843: Therapeutic implication of pH/hypoxic responsive nanoencapsulated tunicamycin on pancreatic cancer by targeting K-RasG12D	44
Abstract 3510: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy	43
Abstract 2696: Targeting SLC7A11 creates a favorable immune microenvironment in colorectal cancer	43
Abstract 2232: BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model	43
Abstract 242: Differential activation of TAM receptors by Gas6 and protein S	43
Abstract 3261: Plasma whole-genome sequencing to monitor pancreatic cancer	42
Abstract 3603: Racial and ethnic disparities in colorectal cancer-specific mortality: The Multiethnic Cohort	42
Abstract 5761: Unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells reveals molecular interplay between protein regulation and metabolic rewiring	42
Abstract 4772: AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)	42
Abstract 3887: Clonal expansion in the bile duct associated with primary sclerosing cholangitis	42
Abstract 1718: Role of IKKε in resistance to second-generation hormone therapy in prostate cancer	42
Abstract 2954: CS5007: A novel EGFR and HER3 dual-targeted antibody-drug conjugate (ADC) with potent antitumor activity in preclinical studies	42
Abstract 5690: Targeting MET activation in CDH1 deficient diffuse gastric cancer with peritoneal metastases	42
Abstract 4192: Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors	42
Abstract 1772: A novel small molecule inhibitor, HO-4200, modulates macrophage polarization and suppresses MDSCs to enhance antitumor immune responses in ovarian cancer	41
Abstract 3849: Pygo2 deletion stimulates tertiary lymphoid structure formation and forms the cornerstone for a quadruple combination immunotherapy of prostate cancer	41
Abstract 2670: Understanding cell-of-origin influence on cancer-associated fibroblasts in lung adenocarcinoma	40
Abstract 5956: Glioblastoma in Appalachia: A retrospective analysis	40
Abstract 2933: IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1	40
Abstract 1632: EGFR-TKIs facilitate cuproptosis via regulating SLC31A1 in cancer cells	40
Abstract 4224: The pharmacological intervention of protein arginine methyltransferase 1 (PRMT1) leads to metastatic castration-resistant prostate cancer (mCRPC) repression through unique and significa	40

Abstract 5017: A multimodal deep learning approach to predict survival in never smoking lung cancer patients	40
Abstract 6327: Prevention of glioblastoma cell growth by Vialinin A	40
Abstract 2250: UCHL1 hijacks tolerogenic DC maturation and promotes mregDC-Treg crosstalk to nullify anti-PD-L1 therapy	39
Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data	38
Abstract 5131: Dysregulated cholesterol metabolism facilitates epithelial-to-mesenchymal transition and tumor progression in colorectal cancer	38
Abstract 5750: Discovery of GSK4418959 (IDE275): A novel, non-covalent, reversible Werner Helicase inhibitor and a new potential therapeutic for the treatment of MSI-H cancers	38
Abstract 3848: Smoking promotes angiogenesis and epithelial to mesenchymal transition in breast cancer	38
Abstract 3997: Advancing precision cancer medicine with patient-derived organoids: an endometrial cancer case study	37
Abstract 1783: Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors	37
Abstract 2028: Development of a miRNA-based prognostic signature for clear cell renal cell carcinoma	37
Abstract 5887: NALCN promoter methylation as a biomarker for metastatic risk in a cohort of non-small cell lung cancer patients	37
Abstract 6065: Preclinical evaluation of LM-168: A next-generation anti-CTLA4 antibody with promising efficacy and reduced toxicity	37
Abstract 3842: ZNF217 promotes breast tumor progression by facilitating angiogenesis	36
Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody	36
Abstract 7092: The change in Asian American/Native American/Pacific Islander demographics in interventional clinical trials in Hawai'i	36
Abstract 5333: CDK4/6 inhibitors in patients with bone-only metastatic breast cancer, the role of immune microenvironment	36
Abstract 5379: NNMT loss drives prostate cancer progression through epigenetic and metabolic reprogramming	36
Abstract 3216: A dual-acting chimeric peptide inhibits tumor growth by inhibiting PD-L1 and inducing immunogenic cell death	36
Abstract 6302: A CellProfiler pipeline for RNAscope analyzing multiple markers across adjacent tissue sections spatially	35
Abstract 6114: Engineering novel synNotch CAR T cells to precisely and effectively target medulloblastoma	35
Abstract 6762: Baseline multiomics and chemotherapy efficacy in preclinical trials using patient-derived xenograft models of cholangiocarcinoma can reveal distinct signatures of chemotherapy response	35
Abstract 6337: A novel PMS2 mutant Lynch syndrome mouse model for cancer prevention studies	35
Abstract 2513: Factors influencing participant attrition in Phase 0 hybrid clinical trials for patients with high-grade glioma	35
Abstract 6826: PRMT5 inhibition is a promising therapeutic strategy for high-risk neuroblastoma	35
Abstract 5671: Development of HTS enzymatic assays for VPS4A and related ATPases	34
Abstract 5649: Potentiation of AKR1C3- and P53-dependent AST-3424 activity via PUMA-mediated degradation of Rad51	34
Abstract 5708: Investigating the role of SMYD3 in medulloblastoma progression and treatment response: Implications for targeted therapy	34
Abstract 6880: Rinatabart sesutecan (PRO1184) in combination with standard-of-care therapy exerted potentiated antitumor activity in preclinical cancer models	34
Abstract 7008: Development of a potent SOS1 degrader exhibiting superior combination effects with anti-cancer drugs in various tumor models	34
Abstract 6991: Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (CRPC)	34
Abstract 6310: Bridging spatial proteomics and classical histopathology: advanced spatial analysis through H&E-enhanced multiplexed immunoprofiling	34
Abstract 4862: Targeting fli1 improves antitumor response of CD8 T cells by promoting their activation and limiting exhaustion	34
Abstract 6996: Integrating high-throughput screening with ligand-based pharmacophore modeling and virtual screening strategies to optimize exonuclease 1 inhibitor design	34
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC	34
Abstract 4867: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications	34
Abstract 7306: Selective and novel ALDH1 inhibitor enhances immune checkpoint blockade therapy in preclinical models of MSS colorectal cancer	34
Abstract 7189: EED inhibitor APG-5918 renders vulnerability to immunotherapy by rewiring sphingolipid metabolism via nSMase2-ceramide pathway in pancreatic cancer	34
Abstract 4002: Development of an organoid coculture model to investigate tumor immune interactions and therapeutic strategies in prostate cancer	34
Abstract 6939: MAPKAP kinase 2 regulates inflammatory responses in glioblastoma	34
Abstract 6755: Discovery of the synergistic dual-payload antibody-drug conjugate (CTPH-02) by combination of MMAE and novel payloads	34
Abstract 7449: Evaluating the effectiveness of machine learning models using polygenic risk scores and clinical factors for breast cancer risk stratification	34
Abstract 4653: Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs	33
Abstract 6400: Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG/DMG	33
Abstract 3824: Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance	33
Abstract 3514: AZD6621: Improving the therapeutic index for prostate cancer T cell engagers with a next-generation CD8-guided format	33
Abstract 3163: Discovery of highly selective ligands for the Bcl-2 family of proteins using DNA-encoded chemical libraries	33
Abstract 7229: Humanized mouse models of γδ T engraftment for the testing of cell based anti-cancer therapeutics	33
Abstract 3159: The 5-base genome, a simultaneous detection of genomic and methylation signatures using a concise, integrated multiomic library prep	32
Abstract 3810: Targeting the ADAR1/PKR pathway in TP53-mutant acute myeloid leukemia	32
Abstract 3224: An indirect Meta-analysis of efficacy and safety of PD-1 inhibitors versus PD-L1 inhibitors as preoperative therapy in patients with solid tumors	32
Abstract 4014: Prognostic evaluation of breast cancer long-term survival outcomes: contributions from a Brazilian hospital-based cohort	32
Abstract 4914: Association of HOXB13 G84E with prostate cancer among 592, 158 men	32
Abstract 1762: Preclinical and clinical studies of PEP07, a novel brain penetrating oral Chk1 inhibitor, on AML and MCL treatments	32
Abstract 5544: Identification, isolation and molecular characterization of drug-resistant sub-populations of pancreatic cancer cells	32
Abstract 5774: Enhancing urothelial carcinoma treatment with nectin-4-PET: A predictor of enfortumab vedotin efficacy	32
Abstract 1504: Harnessing the power of mangifera indica: Activation of Nrf2 by leaf-derived oxylipins	31
Abstract 5755: Expansion of the known functional diversity of human T cells achieved due to the unprecedented resolution of intracellular proteins by mass cytometry (CyTOF)	31
Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS)	31
Abstract CT072: First in human trial of Q702 in patients with advanced solid tumors	31
Abstract 5778: Intra-operative visualization of metastatic sentinel lymph nodes in early breast cancer: An approach to omission of axillary surgery	31
Abstract 2405: NGS-based molecular profiling reveals remarkable anticancer synergy of EZH1/2 dual inhibitor HM97662 with standard-of-care therapy on small cell lung cancer	31
Abstract LB009: Safety profile assessment for IND-enabling studies: Bispecific antibodies and antibody-drug conjugates (ADCs)	31
Abstract 5753: Multi-omic analysis links neighborhood disadvantage to elevated stress hormones and tumorigenic markers in ER+ breast cancer patient plasma and tumor samples	31
Abstract 4831: DNA methylation of immune synapse genes drives tumor immune evasion	31
Abstract LB025: Spatiotemporally regulated expression of membrane-bound interleukin 12 (mbIL12) for armored adoptive cell therapy (ACT) shows strong antitumor activity in syngeneic solid tumor models	31
Abstract LB014: HSK46256, a highly selective and brain penetrable PARP1 inhibitor for the treatment of HRD cancers	31
Abstract CT194: First-in-human, phase 1/2 study of GSK4418959, an oral Werner DNA helicase inhibitor, alone or combined with other anticancer agents in adults with advanced mismatch repair-deficient o	30
Abstract LB306: 3D epigenomic analysis reveals non-coding DNA regions that can reverse prostate cancer phenotypes	30
Abstract LB247: Effects of health insurance on survival for five common cancers in China: A multicenter, hospital-based, retrospective cohort study	30
Abstract LB197: Efficacy, safety, and protein markers of PD-1 inhibitors plus metronomic oral vinorelbine in elderly metastatic non-small-cell lung cancer patients	30
Abstract LB084: Fzd7 promotes melanoma growth via fostering an immunosuppressive tumor microenvironment	30
Abstract LB452: The role of dysregulated retinoid receptors in colorectal cancer	30
Abstract LB070: Trefoil factor I (TFF1) as a modulator of intrinsic and stroma induced chemoresistance in pancreatic ductal adenocarcinoma	30
Abstract LB323: Thioredoxin interacting protein (TXNIP), a regulator of oxidative stress, mediates the RAPGEF3/4 (EPAC1/2) signaling required for melanoma progression	30
Abstract LB309: Differential DNA methylation analysis and functional insights in luminal A and triple-negative breast cancer using FFPE samples	29
Stayin' Alive: Targeting Chromatin Regulators of Clonal Hematopoiesis Promotes CD8 T-cell Stemness	29
Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity	29
Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer	29
Targeting Metabolic Dependencies Fueling the TCA Cycle to Circumvent Therapy Resistance in Acute Myeloid Leukemia	29
PROX1: A Key Regulator of Hepatocyte Identity and Tumorigenesis	29
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers	29
Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-	29
Engineered SH3-Derived Sherpabodies Function as a Modular Platform for Targeted T-cell Immunotherapy	29
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group	29
Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast can	29
Abstract SY22-03: Multifaceted mitochondria in the regulation of chromosome inheritance	29
Abstract LB149: Predicted gut microbial metabolites and chemotherapy induced toxicity among breast cancer patients	29
Leveraging Tissue-Specific Enhancer–Target Gene Regulatory Networks Identifies Enhancer Somatic Mutations That Functionally Impact Lung Cancer	29
Editor’s Note: A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells	29
FOXP4 Is a Direct YAP1 Target That Promotes Gastric Cancer Stemness and Drives Metastasis	29
Abstract LB129: VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases	28
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer	28
Abstract CT247: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers	28
Structure, Dynamics, and Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma	28
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma	28